Moreover, the promoter methylation level of PAX8 in the endometrial cancer tissues with TP53 mutation was also lower than that in the TP53 non-mutated group (Fig. 2E), and the expression pattern of PAX8 was just the opposite (Fig. 2F). This evidence concerns the gene TP53 and endometrial cancer.